Guido Parodi1, Benedetta Bellandi2, Renato Valenti2, Angela Migliorini2, Rossella Marcucci3, Nazario Carrabba2, Letizia Giurlani2, Gian Franco Gensini4, Rosanna Abbate3, David Antoniucci2. 1. Department of Heart and Vessels, Careggi Hospital, Florence, Italy. Electronic address: parodiguido@gmail.com. 2. Department of Heart and Vessels, Careggi Hospital, Florence, Italy. 3. Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy. 4. Department of Heart and Vessels, Careggi Hospital, Florence, Italy; Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy; Don Carlo Gnocchi Foundation, Florence, Italy.
Abstract
UNLABELLED: In ST-elevation myocardial infarction (STEMI) patients, residual platelet reactivity soon after a loading dose (LD) of prasugrel or ticagrelor is higher than that reported for healthy volunteers or subjects with stable coronary artery disease; and the majority of primary percutaneous coronary intervention (PPCI) procedures withbivalirudin monotherapy are performed without proper platelet inhibition. However, ticagrelor LD is just the daily dose, whereas prasugrel LD is 6-fold the long-term daily dose. We hypothesized that an increased ticagrelor LD may result in a faster and more effective platelet inhibition as compared with the standard prasugrel LD. METHODS:Fifty patients with STEMI, pretreated withintravenous aspirin, undergoing PPCI were randomized to receive prasugrel60-mg LD (n = 25) or ticagrelor360-mg LD (n = 25). Residual platelet reactivity was assessed by VerifyNow at baseline and 1, 2, 4, and 12 hours after drug LD. RESULTS: At the time of LD, 90% of enrolled patients had an aspirin reactivity unit value <550. P2Y12 reaction units 1 hour after the LD (study primary end point) were 236 (129-289) and 248 (115-304) in the prasugrel and ticagrelor group, respectively (P = .899). High residual platelet reactivity (P2Y12 reaction units ≥240) was found in 43% and 56% of patients (P = .386) at 1 hour and in 30% and 32% of patients (P = .907) at 2 hours, respectively. There was no significant difference in bleeding, arrhythmias, or dyspnea episodes in the 2 groups. CONCLUSIONS: In patients with STEMI undergoing PPCI, double (360 mg) ticagrelor LD failed to achieve a faster and more intense platelet inhibition as compared with the standard prasugrel LD. Intravenously administered aspirin allowed to achieve a very early inhibition of acid arachidonic pathway.
RCT Entities:
UNLABELLED: In ST-elevation myocardial infarction (STEMI) patients, residual platelet reactivity soon after a loading dose (LD) of prasugrel or ticagrelor is higher than that reported for healthy volunteers or subjects with stable coronary artery disease; and the majority of primary percutaneous coronary intervention (PPCI) procedures with bivalirudin monotherapy are performed without proper platelet inhibition. However, ticagrelor LD is just the daily dose, whereas prasugrel LD is 6-fold the long-term daily dose. We hypothesized that an increased ticagrelor LD may result in a faster and more effective platelet inhibition as compared with the standard prasugrel LD. METHODS: Fifty patients with STEMI, pretreated with intravenous aspirin, undergoing PPCI were randomized to receive prasugrel 60-mg LD (n = 25) or ticagrelor 360-mg LD (n = 25). Residual platelet reactivity was assessed by VerifyNow at baseline and 1, 2, 4, and 12 hours after drug LD. RESULTS: At the time of LD, 90% of enrolled patients had an aspirin reactivity unit value <550. P2Y12 reaction units 1 hour after the LD (study primary end point) were 236 (129-289) and 248 (115-304) in the prasugrel and ticagrelor group, respectively (P = .899). High residual platelet reactivity (P2Y12 reaction units ≥240) was found in 43% and 56% of patients (P = .386) at 1 hour and in 30% and 32% of patients (P = .907) at 2 hours, respectively. There was no significant difference in bleeding, arrhythmias, or dyspnea episodes in the 2 groups. CONCLUSIONS: In patients with STEMI undergoing PPCI, double (360 mg) ticagrelor LD failed to achieve a faster and more intense platelet inhibition as compared with the standard prasugrel LD. Intravenously administered aspirin allowed to achieve a very early inhibition of acid arachidonic pathway.
Authors: Himawan Fernando; Ziad Nehme; Karlheinz Peter; Stephen Bernard; Michael Stephenson; Janet E Bray; Paul S Myles; Romi Stub; Peter Cameron; Andris H Ellims; Andrew J Taylor; David M Kaye; Karen Smith; Dion Stub Journal: Int J Cardiol Heart Vasc Date: 2021-11-08
Authors: Jacek Kubica; Piotr Adamski; Małgorzata Ostrowska; Joanna Sikora; Julia Maria Kubica; Wiktor Dariusz Sroka; Katarzyna Stankowska; Katarzyna Buszko; Eliano Pio Navarese; Bernd Jilma; Jolanta Maria Siller-Matula; Michał Piotr Marszałł; Danuta Rość; Marek Koziński Journal: Eur Heart J Date: 2015-10-21 Impact factor: 29.983
Authors: Christopher Reid; Ahmed Alturki; Andrew Yan; Derek So; Dennis Ko; Jean-Francois Tanguay; Amal Bessissow; Shamir Mehta; Shaun Goodman; Thao Huynh Journal: CJC Open Date: 2020-02-24